Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
about
Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C VirusHepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C TherapyGenome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis CGenome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CPrediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.Risk prediction models for hepatocellular carcinoma in different populations.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patientsHepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsAnalysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinomaSustained virological response: a milestone in the treatment of chronic hepatitis C.Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.Retreatment of chronic hepatitis C in previous non-responders and relapsers.Long-term effects of interferon-based therapy for chronic hepatitis C.Durability of sustained virologic response in chronic hepatitis C.An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy.Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases.Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside.Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Natural history of HCV infection.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.Prediction of recurrence following hepatectomy in patients with hepatitis C virus infection-related hepatocellular carcinoma who achieved a sustained virological response.ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection.Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
P2860
Q26765245-2E845FDF-1047-4B46-915E-05E810BF1E18Q26795750-D52BCE47-2EEE-45A2-AA7A-29D9E7BA806BQ28254011-B9CD64C2-DF5D-4380-B355-0886594ED541Q28943467-AF6D4C39-BDBF-4346-9C40-23ACE6824185Q30374727-4E9E5054-8508-427D-91B3-BB4BF2E8E5D4Q30383460-F0F9C39C-BEA3-4EC8-B20B-AA05EBE642FDQ30479629-8B84A8B2-CE29-45C9-8B51-32465DF313DAQ33430028-D4FB9AF1-6E72-4C71-947A-DEC1C66026E2Q33576524-5810E67E-120F-4E3F-B437-12F67B8978E4Q33866448-8FCBF94C-05BB-43B0-AA95-2DD84FD2626EQ33905607-43365240-8F96-48DF-9294-4E8A4EF12BEFQ34987336-6784F5D5-DDE0-4974-A130-9DF2BEDCC6C1Q35077047-2E37DE06-CF7B-4DE0-A8ED-EF353D31181CQ35112598-BF61607D-B4E4-4467-BB5D-AD13C80DC638Q36159403-79A7F4DA-AE63-4D59-9489-0DB9CC5BFEE8Q36497089-94367ED8-905B-4006-8A1A-E9AC572ACD12Q36841325-4053378C-6D6F-4EF5-83FD-AAC71A7DA8CAQ36906147-757AB38B-52B7-4ADB-B11D-73E03D14E85EQ36968144-01B54B5A-F6A8-4427-8ED4-7C03924FEEE2Q37034868-6032DD4C-8945-4872-ABF0-2919F010E580Q37046571-132A2881-79AE-4699-905F-966C753F476DQ37055955-B08A2043-D0A4-46B6-9E80-C755893445B0Q37266324-65B158F2-6BDD-44F4-ABE7-86B17A0857D0Q37871559-D0F682A4-1F6A-4ED4-AEDA-BF4A30B7329DQ38046452-355868E4-5626-4B38-AD08-F02409504388Q38170161-5403563F-8244-4620-8737-4CC27C8F48A3Q38552179-8094BA26-5052-4247-BC31-3A32F8EAAB67Q38758591-360A4F18-D5A3-428A-9901-EF1DFFDB6478Q39877443-FF1B8E0C-7EFF-41DD-B647-C6EB5250CE9AQ40087272-65A55F05-8192-42AF-ACBE-FB46768B5063Q40281588-17D4D5E0-4AFA-4F6C-8AF2-7DA87CD5D474Q40362177-043A4311-FB45-46E1-BBCF-EAD9EB95E1FCQ40531340-32AB3FFD-F0EB-477C-83E5-B4361AD29B1FQ40707640-017B74A2-1BB8-4B95-82F1-91DB74766C47Q40873258-E786ED73-F96F-4E5F-8905-487A9BB4F358Q40903867-874D73B9-F08F-4ABB-996B-5AC9EFCEF89BQ41654105-587D98E0-9DFD-482C-98C3-355B51D6B8CEQ41767801-4D20FDEF-F948-4D46-91C6-3AEF00AB9585Q41962614-443A4369-8E4D-4897-928D-8C0FD86A2E36Q42223359-EF85B154-4601-491A-A7FF-A768D92097FC
P2860
Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@ast
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@en
type
label
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@ast
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@en
prefLabel
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@ast
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@en
P2093
P2860
P356
P1433
P1476
Benefit of interferon therapy ...... ents with chronic hepatitis C.
@en
P2093
H Ishibashi
O Yokosuka
R Tateishi
S Fujiyama
S Nishiguchi
P2860
P304
P356
10.1136/GUT.2003.030353
P407
P577
2004-03-01T00:00:00Z